Head & Neck Cancers | Specialty

Novel Biomarker May Predict Recurrence in HPV+ Oropharyngeal Cancer

January 14th 2017

In the current treatment landscape of HPV-positive oropharyngeal squamous cell carcinoma, there is a significant lack of biomarkers to predict recurrence.

Robotic Surgery Represents a Notable Advance in Thyroid Cancer Care

January 13th 2017

Amid a rising incidence of thyroid cancer, endocrine surgeons have increasingly explored minimally invasive approaches for operating on patients with the disease.

Reduced-Dose Radiation Effective in HPV-Associated Oropharynx Cancers

January 6th 2017

Induction chemotherapy followed by reduced-dose radiation and weekly cetuximab demonstrated improved swallowing and nutritional status as well as an excellent complete clinical response for patients with HPV-associated oropharyngeal squamous cell carcinoma.

Dr. Vokes on Moving Immunotherapy into Frontline for Head and Neck Cancer

January 6th 2017

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses the possibility of moving immunotherapy agents into the frontline setting for patients with head and neck cancer.

Immunotherapies Form New Frontier in Treating Head and Neck Cancers

January 2nd 2017

In August 2016, the FDA approved pembrolizumab for patients with platinum-refractory squamous cell carcinoma of the head and neck. Not only was it the first immunotherapy approved for head and neck cancer (HNC), but it marked the first new drug approval for HNC in the United States in 20 years.

Dr. Vokes on Selecting Nivolumab or Pembrolizumab for Head and Neck Cancer Treatment

December 28th 2016

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses how to choose between nivolumab (Opdivo) and pembrolizumab (Keytruda) for second-line treatment for patients with head and neck cancer.

Dr. Burtness on Treatment Approaches in HPV-Positive Head and Neck Cancer

December 27th 2016

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses current treatment approaches for patients with human pappillomavirus (HPV)-positive head and neck cancer, as well as potential changes for those regimens.

Distinct, Aggressive Subgroup of ACC Identified With Activating NOTCH1 Mutations

December 23rd 2016

NOTCH1 mutations have been found to define an aggressive subgroup of patients with adenoid cystic carcinomas, with a corresponding pattern of metastatic spread.

Dr. Seiwert on Prognosis for Patients With Head and Neck Cancer

December 23rd 2016

Tanguy Y. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the current prognosis for patients with head and neck cancer prior to the FDA approvals of immunotherapy agents nivolumab (Opdivo) and pembrolizumab (Keytruda) as treatments.

Emerging PD-L1 Inhibitors for HNSCC

December 22nd 2016

Ongoing Research of Immunotherapy in HNSCC

December 22nd 2016

Patient Selection for Nivolumab in HNSCC

December 22nd 2016

Nivolumab-Related Efficacy and Toxicity in HNSCC Patients

December 22nd 2016

Nivolumab: A New Standard-of-Care

December 22nd 2016

Immunotherapy for Recurrent HNSCC

December 22nd 2016

The Approval of Pembrolizumab for Recurrent HNSCC

December 22nd 2016

Immunotherapy for Virally Induced vs High-Mutation Burden HNSCC

December 22nd 2016

Mechanisms of Immunotherapy in HNSCC

December 22nd 2016

Historic Perspective on Recurrent HNSCC

December 22nd 2016

Historic Perspective on Systemic Therapy for Advanced HNSCC

December 22nd 2016